CA3191452A1 - Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists - Google Patents
Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonistsInfo
- Publication number
- CA3191452A1 CA3191452A1 CA3191452A CA3191452A CA3191452A1 CA 3191452 A1 CA3191452 A1 CA 3191452A1 CA 3191452 A CA3191452 A CA 3191452A CA 3191452 A CA3191452 A CA 3191452A CA 3191452 A1 CA3191452 A1 CA 3191452A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- substituted
- ring
- occurrence
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020108325 | 2020-08-11 | ||
| CNPCT/CN2020/108325 | 2020-08-11 | ||
| PCT/IB2021/059266 WO2022034568A1 (en) | 2020-08-11 | 2021-10-09 | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3191452A1 true CA3191452A1 (en) | 2022-02-17 |
Family
ID=78179477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3191452A Pending CA3191452A1 (en) | 2020-08-11 | 2021-10-09 | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4196220A1 (enExample) |
| JP (2) | JP2023544476A (enExample) |
| KR (1) | KR20240068583A (enExample) |
| CN (1) | CN116669727B (enExample) |
| AU (1) | AU2021323515A1 (enExample) |
| CA (1) | CA3191452A1 (enExample) |
| IL (1) | IL300525A (enExample) |
| MX (1) | MX2023001812A (enExample) |
| WO (1) | WO2022034568A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| CN117751106A (zh) * | 2021-04-30 | 2024-03-22 | 唯久生物技术(苏州)有限公司 | 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物 |
| AU2022273631B2 (en) | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物 |
| WO2024022314A1 (zh) * | 2022-07-25 | 2024-02-01 | 武汉人福创新药物研发中心有限公司 | 三氮唑类化合物及其作为lpar1拮抗剂的用途 |
| CN121773091A (zh) * | 2023-09-08 | 2026-03-31 | 西藏海思科制药有限公司 | 杂芳环衍生物的lpar1拮抗剂及其用途 |
| WO2025162421A1 (zh) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | Lpar1拮抗剂及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1364659B1 (en) * | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| JP5931721B2 (ja) * | 2009-06-16 | 2016-06-08 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ | アシルＣｏＡリゾリン脂質アシルトランスフェラーゼの発現による長鎖オメガ−３及びオメガ−６多価不飽和脂肪酸生合成の改良 |
| US8785442B2 (en) * | 2011-01-30 | 2014-07-22 | Curegenix, Inc. | Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| EP2922823B1 (en) | 2012-11-20 | 2018-10-31 | Merck Sharp & Dohme Corp. | Pyrimidine pde10 inhibitors |
| US20140200215A1 (en) * | 2013-01-15 | 2014-07-17 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| SG11201507459YA (en) * | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
| CN111712492B (zh) * | 2017-12-19 | 2024-05-31 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸三唑唑类 |
| CA3085561A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azines as lpa antagonists |
| WO2019126087A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| JP7202383B2 (ja) * | 2017-12-19 | 2023-01-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| ES2946657T3 (es) * | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
-
2021
- 2021-10-09 IL IL300525A patent/IL300525A/en unknown
- 2021-10-09 MX MX2023001812A patent/MX2023001812A/es unknown
- 2021-10-09 CN CN202180067597.XA patent/CN116669727B/zh active Active
- 2021-10-09 CA CA3191452A patent/CA3191452A1/en active Pending
- 2021-10-09 JP JP2023510342A patent/JP2023544476A/ja active Pending
- 2021-10-09 KR KR1020237008152A patent/KR20240068583A/ko active Pending
- 2021-10-09 WO PCT/IB2021/059266 patent/WO2022034568A1/en not_active Ceased
- 2021-10-09 EP EP21791479.5A patent/EP4196220A1/en active Pending
- 2021-10-09 AU AU2021323515A patent/AU2021323515A1/en active Pending
-
2026
- 2026-02-12 JP JP2026020642A patent/JP2026086696A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL300525A (en) | 2023-04-01 |
| AU2021323515A1 (en) | 2023-03-09 |
| CN116669727A (zh) | 2023-08-29 |
| WO2022034568A1 (en) | 2022-02-17 |
| KR20240068583A (ko) | 2024-05-17 |
| CN116669727B (zh) | 2025-07-08 |
| JP2023544476A (ja) | 2023-10-24 |
| MX2023001812A (es) | 2023-06-19 |
| EP4196220A1 (en) | 2023-06-21 |
| JP2026086696A (ja) | 2026-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116669727B (zh) | 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物 | |
| CA3124898C (en) | Heterocyclic compound, intermediate, preparation method therefor and application thereof | |
| AU2007311591B2 (en) | Biaryl ether urea compounds | |
| JP7577655B2 (ja) | 環状尿素 | |
| EP4333899A1 (en) | Compounds for targeting degradation of bruton's tyrosine kinase | |
| CA3085561A1 (en) | Cyclohexyl acid triazole azines as lpa antagonists | |
| BR112016011024B1 (pt) | Composto, composição farmacêutica, e, usos dos mesmos | |
| WO2013066729A1 (en) | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors | |
| WO2022165513A1 (en) | Cdk2 inhibitors and methods of using the same | |
| CA3218258A1 (en) | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists | |
| JP2024537110A (ja) | Ｅｎｔ１阻害活性を有する大環状化合物 | |
| WO2024026483A2 (en) | Cdk2 inhibitors and methods of using the same | |
| CN101663276A (zh) | 用作激酶抑制剂的2-氨基吡啶衍生物 | |
| WO2023086521A1 (en) | Btk inhibitors | |
| IL296602A (en) | n-(Heterocyclyl and heterocyclylalkyl)-3-benzylpyridine-2-amine derivatives as sstr4 agonists | |
| HK40100136A (zh) | 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241119 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250918 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250918 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250918 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250922 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250922 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251118 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251118 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251118 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251118 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251119 |